Zhenping Wu
Corporate Officer/Principal chez Hutchison MediPharma Ltd.
Profil
Zhenping Wu is a Senior Vice President-Pharmaceutical Sciences at Hutchison MediPharma Ltd.
He previously held positions as Chairman & President at Sino-American Biotechnology & Pharmaceutical Professional, Senior Director-Pharmaceutical Sciences at Phenomix Corp., Director-Pharmaceutical Development at Pfizer (St. Louis), and Senior Scientist at Roche Corp.
He holds a doctorate degree from the University of Hong Kong and an MBA degree from the University of California, Irvine.
Postes actifs de Zhenping Wu
| Sociétés | Poste | Début |
|---|---|---|
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 24/03/2010 |
Anciens postes connus de Zhenping Wu
| Sociétés | Poste | Fin |
|---|---|---|
| Sino-American Biotechnology & Pharmaceutical Professional | Président | - |
Pfizer (St. Louis)
 Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Corporate Officer/Principal | - |
| Roche Corp. | Corporate Officer/Principal | - |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | - |
Formation de Zhenping Wu
| University of Hong Kong | Doctorate Degree |
| University of California, Irvine | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
| Roche Corp. | |
| Sino-American Biotechnology & Pharmaceutical Professional |